CA-ESRI
5.10.2021 15:02:11 CEST | Business Wire | Press release
Global construction challenges, from affordable housing availability to infrastructure stress as a result of climate change, have increased in recent years. As a result, governments and commercial organizations will need to invest trillions of dollars in the next decade in mitigation and recovery processes. By adopting building information modeling (BIM) and geographic information system (GIS) technology, the architecture, engineering, and construction (AEC) industry improved construction, design, and operations efficiency. Recognizing the benefits for project outcomes that a combined BIM and GIS software would present, Esri , the global leader in location intelligence, joined forces with Autodesk in 2017. The partnership produced new technology, integrating the power of mapping into the BIM process.
Today, Esri is releasing a new product that expands the ability for BIM project teams to benefit from GIS. ArcGIS GeoBIM provides an innovative, easy-to-use web-based experience for AEC teams to explore and collaborate using data from multiple systems in a geospatial context. ArcGIS GeoBIM connects to Autodesk BIM Collaborate Pro , a cloud-based design collaboration, coordination, and model coauthoring software built on the Autodesk Construction Cloud .
"With many global initiatives under way to improve construction, design, and planning practices, it is critical that today's AEC professionals can collaborate together with a common view of assets in a geospatial context," said Jack Dangermond, Esri founder and president. "The ability to operate without siloed data provides AEC professionals with the flexibility they need to work together and meet the challenges of building in the future on an unprecedented scale."
ArcGIS GeoBIM will provide project leaders and stakeholders in industries like infrastructure, construction, planning, water, and transportation with a common view of asset locations, costs, issues, risks, and timelines throughout the project life cycle.
"Autodesk and Esri's cloud-to-cloud connection gives our shared customers a unified experience and the information they need at their fingertips—regardless of whether it's BIM or GIS data," said Amy Bunszel, Autodesk executive vice president of AEC Design Solutions. "This will improve efficiency and decision-making during planning, construction, and operations. Ultimately, our collaboration will help enable the industry to deliver more sustainable and resilient infrastructure."
AEC team members can track design, coordination, quality, safety, and commissioning issues by linking data from Autodesk BIM Collaborate with ArcGIS GeoBIM.
"What we need is a single, authoritative source of truth access point for everyone on our team, a way to bring data and information together that originates from multiple formats," said Darin Welch, HNTB associate vice president and national geospatial and virtual engagement manager. "Esri's ArcGIS GeoBIM connection to the Autodesk Construction Cloud combines survey, design, and planning workflows that offer a blended BIM-GIS data experience that equips our team with more informed decision-making."
ArcGIS GeoBIM is available for widespread use as of October 4, 2021. For more information and to stay up-to-date on the latest offerings, visit go.esri.com/geobim-pr .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, GeoBIM, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
Autodesk and Autodesk Construction Cloud are registered trademarks of Autodesk, Inc., in the USA and/or other countries .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005638/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom